Friday, 24 November

17:50-18:30

Plenary Lecture 1
Moderator: Ian M. Gould (United Kingdom)

HUMA Lecture:

β-Lactamases as we see them today
Karen Bush (United States)
08:50-09:30
Plenary Lecture 2
Moderator: Po-Ren Hsueh (Taiwan)

Novel antibiotics on the horizon
David M. Livermore (United Kingdom)

09:30-10:00
Plenary Hall

Keynote Lecture 1
Moderator: Karen Bush (United States)

Chlorhexidine bathing and nasal decolonisation to prevent infection and reduce antibiotic resistant pathogens
Susan S Huang (United States)

09:30-10:00
Room 201ABC

Keynote Lecture 2
Moderator: Pei-Jer Chen (Taiwan)

Risk stratification and treatment of chronic Hepatitis B: towards the eradication of Hepatitis B virus infection
Jia-Horng Kao (Taiwan)

09:30-10:00
Room 201DEF

Keynote Lecture 3
Moderator: David M. Livermore (United Kingdom)

In “CAST” we trust – but which of the many?
Gunnar Kahlmeter (Sweden)

09:30-10:00
Room 102

Keynote Lecture 4
Moderator: Lionel Ari Mandell (Canada)

Update of pneumonia guidelines: Japan vs. Global
Shigeru Kohno (Japan)
10:30-12:00  
**Symposium 1**  
**Control of carbapenemase producing *Enterobacteriaceae (CPE)***  
Co-organised by the Society of Infectious Disease (Singapore)  
Moderators: David Chien Boon Lye (Singapore); Jiunn-Jong Wu (Taiwan)

**SP 1-1**  
CPE: the antimicrobial stewardship approach  
Wen-Chien Ko (Taiwan)

**SP 1-2**  
CPE: the infection control approach  
Vincent Cheng (Hong Kong)

**SP 1-3**  
CPE: treatment options  
David Chien Boon Lye (Singapore)

10:30-12:00  
**Symposium 2**  
**MRSA: global epidemiology and treatment**  
Co-organised by the ISC MRSA Working Group  
Moderators: Dale Fisher (Singapore); Chun-Hsing Liao (Taiwan)

**SP 2-1**  
Global epidemiology of MRSA: how community acquired-MRSA impacts on clinical practice?  
Shey-Ying Chen (Taiwan)

**SP 2-2**  
Treatment and eradication of community acquired-MRSA  
Ian M. Gould (United Kingdom)

**SP 2-3**  
New agents for MRSA: recently released or in the pipeline  
Paul Tulkens (Belgium)

**SP 2-4**  
Livestock associated-MRSA epidemiology  
Geoffrey Coombs (Australia)

10:30-12:00  
**Symposium 3**  
**Nontuberculous Mycobacteria (NTM)**  
Co-organised by the ISC Mycobacterial Working Group and Japanese Society of Tuberculosis (JSTB)  
Moderators: Bijie Hu (China); Feng-Yee Chang (Taiwan)

**SP 3-1**  
Epidemiology: global vs. Asian  
Kozo Morimoto (Japan)

**SP 3-2**  
Species versus subspecies: clinical implications  
Won-Jung Koh (Korea)

**SP 3-3**  
Treatment of NTM infections  
Ting-Shu Wu (Taiwan)
## Symposium 4

**Vascular access: problems and solutions**  
**Moderators:** Yoshio Takesue (Japan); Yu-Hui Chen (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 4-1</td>
<td>Epidemiology and impact of peripheral line associated complications</td>
<td>Keita Morikane (Japan)</td>
</tr>
<tr>
<td>SP 4-2</td>
<td>Epidemiology and impact of central line associated complications</td>
<td>Serhat Unal (Turkey)</td>
</tr>
<tr>
<td>SP 4-3</td>
<td>Pitfalls of catheter care in resource-limited settings</td>
<td>Anucha Apisarnthanarak (Thailand)</td>
</tr>
</tbody>
</table>

## Oral Session 1

**Moderators:** Hui Wang (China); Yun F Wayne Wang (United States); Hao-Chieh Chiu (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>OS 1-1</td>
<td>Evaluation of flow cytometry (Sysmex UF1000i) for screening urines for bacteria and white blood cells from patients with suspected urinary tract infection</td>
<td>Joseph Blondeau (Canada)</td>
</tr>
<tr>
<td>OS 1-2</td>
<td>Using MALDI-TOF and selected gene (16S rRNA gene, gyrB gene) sequencing to practically and accurately identify clinically important viridans group streptococci</td>
<td>Menglan Zhou (China)</td>
</tr>
<tr>
<td>OS 1-3</td>
<td>Multiplex PCR assay for identification of Enterococcus species on the basis of groEL gene</td>
<td>Wei-Chun Hung (Taiwan)</td>
</tr>
<tr>
<td>OS 1-4</td>
<td>Comparison of first void urine with urethral swabs for detection of Ureaplasma in male patients with urogenital infections by using culture, sequencing, and isothermal RNA amplification assay</td>
<td>Yali Liu (China)</td>
</tr>
<tr>
<td>OS 1-5</td>
<td>C-reactive protein levels differ between common respiratory viral infections: role of point-of-care testing in detection of influenza infection</td>
<td>Angela Chow (Singapore)</td>
</tr>
<tr>
<td>OS 1-6</td>
<td>Discordance of the vancomycin MIC for methicillin-resistant Staphylococcus aureus at 2 μg/mL between Vitek II, E-test, and broth microdilution</td>
<td>Shin-Yi Tsai (Taiwan)</td>
</tr>
<tr>
<td>OS 1-7</td>
<td>Clostridium difficile MLST clade 4 identification by a simple and reliable MALDI-TOF MS-based method</td>
<td>Jingwei Cheng (China)</td>
</tr>
<tr>
<td>OS 1-8</td>
<td>The epidemic severity and the &quot;epidemic potential&quot; of dengue viruses - Taiwan's experiences to help global control</td>
<td>Chwan-Chuen King (Taiwan)</td>
</tr>
</tbody>
</table>
OS 2-1   Antifungal susceptibility of clinical isolates of 23 genetically confirmed *Aspergillus* species collected from Taiwan and Mainland China
Ying Li (China)

OS 2-2   Proposal of a new scoring system to predict prognosis of Candidaemia patients
Kazumasa Akagi (Japan)

OS 2-3   Antifungal stewardship in a cancer hospital: a pharmacist-led performance improvement programme
Wei-Ting Chen (Taiwan)

OS 2-4   A rare case of *Aspergillus terreus* endogenous endophthalmitis in a non-immunocompromised patient and laboratory research
Ying Zhao (China)

OS 2-5   Epidemiology of candidaemia and antifungal drugs resistance in a teaching hospital in Tangerang, Indonesia
Cucunawangsih (Indonesia)

OS 2-6   The impact of biofilm formation on breakthrough candidaemia
Wei Sin Li (Taiwan)

OS 2-7   MALDI-TOF MS based identification and antifungal susceptibilities of *Trichosporon* isolates causing invasive fungal diseases in China, 2010-2014
Lina Guo (China)

OS 2-8   Anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor
Kimiyasu Shiraki (Japan)

SS 1-1   Worldwide azole resistance and clinical implications for antifungal treatment
Jacques F. Meis (Netherlands)

SS 1-2   Management of yeast Infection in blood: Taiwanese experience
Po-Liang Lu (Taiwan)

SS 1-3   Management of a mucormycosis outbreak
Patrick Chiu Yat Woo (Hong Kong)
Satellite Symposium 2
Evidence based guidelines: patient assessment and vascular access device selection
Organised by Bard Access Systems
Moderators: Mauro Pittiruti (Italy); Chun-Ming Lee (Taiwan)

SS 2-1  Best practice for vascular access device : tips and tricks for better outcomes
        Mauro Pittiruti (Italy)

SS 2-2  Expanding the practice of nurses in vascular access - the French experience
        Herve Rosay (France)

SS 2-3  Different patients; different vascular device requirement: algorithm to choose the right vascular access device
        Girish V Badarkhe (India)

Satellite Symposium 3
Influenza update
Organised by Taiwan Shionogi (TS) & Co., Ltd.
Moderators: Shigeru Kohno (Japan); Po-Ren Hsueh (Taiwan)

SS 3-1  Global epidemiology and health impact
        Shigeru Kohno (Japan)

SS 3-2  Treatment and prevention: what’s new?
        Michael G Ison (United States)

SS 3-3  Taiwanese perspective
        Wang-Huei Sheng (Taiwan)

Satellite Symposium 4
Strategy optimisation for complex infection managements in the MDR era
Organised by Pfizer
Moderators: Shan-Chwen Chang (Taiwan); Yee-Chun Chen (Taiwan)

SS 4-1  Real-life experience in the treatment of complicated intra-abdominal infections (cIAIs)
        Joseph Solomkin (United States)

SS 4-2  Current clinical practice and future developments of the treatment of MRSA pneumonia and skin soft tissue infection
        Jann-Tay Wang (Taiwan)

SS 4-3  The rationale for individualized therapy for complex invasive fungal infection
        Deborah Marriott (Australia)
<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Lecture Description</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00-14:30</td>
<td>Plenary Hall</td>
<td>Keynote Lecture 5</td>
<td>Marc Mendelson (South Africa)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Antibiotic stewardship: the reality</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Ian M. Gould (United Kingdom)</em></td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Room 201ABC</td>
<td>Keynote Lecture 6</td>
<td>Paul Tambyah (Singapore)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>New WHO and CDC guidelines for the prevention of surgical site infections</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Joseph Solomkin (United States)</em></td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Room 201DEF</td>
<td>Keynote Lecture 7</td>
<td>TBA</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>TBA</strong></td>
<td></td>
</tr>
<tr>
<td>14:00-14:30</td>
<td>Room 102</td>
<td>Keynote Lecture 8</td>
<td>Shan-Chwen Chang (Taiwan)</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Emerging zoonotic MERS – CoV disease</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>Ziad A. Memish (Kingdom of Saudi Arabia)</em></td>
<td></td>
</tr>
</tbody>
</table>
### Symposium 5
**Outpatient parenteral antibiotic therapy; stewardship and right siting in Asia**
Co-organised by the ISC OPAT Working Group
**Moderators:** Visanu Thamlikitkul (Thailand); Cheng-Hua Huang (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Presenter/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 5-1</td>
<td>OPAT in Asia</td>
<td>Dale Fisher (Singapore)</td>
</tr>
<tr>
<td>SP 5-2</td>
<td>OPAT in the rest of the world</td>
<td>Mark Gilchrist (United Kingdom)</td>
</tr>
<tr>
<td>SP 5-3</td>
<td>OPAT – an Indian experience</td>
<td>Subramanian Swaminathan (India)</td>
</tr>
</tbody>
</table>

### Symposium 6
**Antiretroviral resistance: an update**
Co-organised by the Taiwan AIDS Society
**Moderators:** Wasun Chantratita (Thailand); Hsi-Hsun Lin (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Presenter/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 6-1</td>
<td>Protease inhibitors in anti-retroviral therapy: past, present and future</td>
<td>Chloe Orkin (United Kingdom)</td>
</tr>
<tr>
<td>SP 6-2</td>
<td>Next generation sequencing: a game-changing tool for HIV drug resistance testing in Thailand</td>
<td>Wasun Chantratita (Thailand)</td>
</tr>
<tr>
<td>SP 6-3</td>
<td>Current status of antiretroviral resistance in Asia-Pacific region</td>
<td>Sui-Yuan Chang (Taiwan)</td>
</tr>
</tbody>
</table>

### Symposium 7
**Colistin resistance: why? what to do? it is possible to go back?**
**Moderators:** Francesco Scaglione (Italy); Yeu-Jun Lau (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Presenter/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 7-1</td>
<td>Enterobacteriaceae</td>
<td>Hui Wang (China)</td>
</tr>
<tr>
<td>SP 7-2</td>
<td>Acinetobacter spp.</td>
<td>Stefania Stefani (Italy)</td>
</tr>
<tr>
<td>SP 7-3</td>
<td>mcr-mediated resistance in animals</td>
<td>Jean-Marc Rolain (France)</td>
</tr>
</tbody>
</table>

### Symposium 8
**Key issues for improving the use of antibiotics**
Co-organised by the ISC Antimicrobial Stewardship Working Group
**Moderators:** Alan Hauser (United States); Shu-Hui Tseng (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Presenter/Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 8-1</td>
<td>De-escalation of empirical antibiotic treatment: when, how and for whom?</td>
<td>Pierre Tattevin (France)</td>
</tr>
<tr>
<td>SP 8-2</td>
<td>Changing behaviour to improve antibiotic stewardship</td>
<td>Victor Lim (Malaysia)</td>
</tr>
<tr>
<td>SP 8-3</td>
<td>Rapid blood culture diagnostics to improve antibiotic therapy</td>
<td>Bert K. Lopansri (United States)</td>
</tr>
</tbody>
</table>
14:30-16:00 Room 103

Oral Session 3
Moderators: Vladimir Krcmery (Slovakia); Chuan-Liang Kao (Taiwan)

OS 3-1 Anal HPV in HIV-infected and HIV-uninfected MSM in Guangzhou: implication for vaccination
Huachun Zou (China)

OS 3-2 Correlations between CD4 count, liver function, and renal functions before HAART among CST clients at Sanglah General Hospital, Bali
Kevin Kristian Putra (Indonesia)

OS 3-3 Primary intracranial diffuse large B-cell lymphoma in acquired immune deficiency syndrome patients with previously treated cryptococcal meningitis
Yukiko Misaki (Japan)

OS 3-4 Takeda’s candidate tetravalent dengue vaccine (TDV) – progress to phase 3
Choo Beng Goh (Singapore)

OS 3-5 Does seropositivity translate to protection against influenza? - A prospective study among HCWs and patients with chronic respiratory diseases
Nandhini Palani (India)

OS 3-6 Characteristics of immunological failure after 12-month-use of first-line HAART among care support and treatment clients in Sanglah Hospital, Bali Province, Indonesia
Muhammad Faisal Putro Utomo (Indonesia)

OS 3-7 Structural insight into peptidic inhibitors of Zika virus NS2B-NS3 protease
Congbao Kang (Singapore)

OS 3-8 Investigation of occult hepatitis B and C in haemodialysis patients
Alper Sener (Turkey)

14:30-16:00 South Lounge

Oral Session 4
Moderators: Bo Zheng (China); Wing Hong Seto (Hong Kong); Chun-Kai Huang (Taiwan)

OS 4-1 Urinary concentrations and bactericidal activity of tobramycin in healthy subjects receiving a single oral dose (600 Milligrams)
Florian Wagenlehner (Germany)

OS 4-2 Effect of toxin production by antibiotics in multidrug-resistant Streptococcus pyogenes
Masaaki Minami (Japan)

OS 4-3 Methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides: a 10-year retrospective study
Katja Seme (Slovenia)

OS 4-4 Ceftolozane / tazobactam resistance in Pseudomonas aeruginosa
Vincent Tam (United States)

OS 4-5 Characterisation of a potential new class of antimicrobial agent for Gram-negative bacteria
Hongfei Pi (Australia)

OS 4-6 High in vitro activity of meropenem/RPX7009 against KPC-producing Enterobacteriaceae in China
Qiwen Yang (China)

OS 4-7 Molecular characterisation of extended spectrum beta-lactamase-producing Gram-negative uropathogens at a specialist hospital in North Western Nigeria
Tanko Nuhu (Nigeria)
OS 4-8  Genotypic variations between wild-type and small colony variants of Staphylococcus aureus in prosthetic valve infectious endocarditis: a comparative genomic and transcriptomic analysis
Jiangang Zhang (China)

16:30-18:00  Plenary Hall
Oral Session 5
Moderators: Mark Gilchrist (United Kingdom); Chien-Hsien Huang (Taiwan)

OS 5-1  Implementation of an antibiotic stewardship program in a Tunisian teaching hospital
Adneen Toumi (Tunisia)

OS 5-2  Impact of early antibiotic therapy (EAT) on outcome of patients with sepsis at the emergency room of National Kidney and Transplant Institute
Irene Rosellen Tan (Philippines)

OS 5-3  Compliance with guidelines and appropriateness of antimicrobial prescribing in Australian hospitals
Rodney James (Australia)

OS 5-4  Significance of antimicrobial treatment-related factors for the outcomes of adult empyemas in Japanese tertiary hospitals
Daisuke Okuno (Japan)

OS 5-5  The impact of an antimicrobial stewardship ward round in a cardiovascular surgical intensive care unit
Ling-Ju Huang (Taiwan)

OS 5-6  Appropriateness of surgical prophylaxis contributed to significant reduction of oral cephalosporins in a Japanese university hospital
Hiroshi Morioka (Japan)

OS 5-7  Do prescribers know why they are ordering antibiotics?
Shermaine Chong (Singapore)

OS 5-8  Molecular mechanism and fitness cost of daptomycin resistant Staphylococcus aureus obtained from in vitro daptomycin ion pressure
Yuyao Yin (China)

16:30-18:00  Room 201ABC
Satellite Symposium 5
New era of STR in HIV-1 infection management
Organised by Gilead Sciences Hong Kong Limited Taiwan Branch
Moderators: Chloe Orkin (United Kingdom); Hsi-Hsun Lin (Taiwan)

SS 5-1  Building the backbone for now and the future; Advancing clinical management in HIV with a novel STR
Chloe Orkin (United Kingdom)

SS 5-2  Early experiences of Genvoya in Hong Kong
Grace Lui (Hong Kong)

SS 5-3  STR perspectives in HIV-1 treatment in Taiwan: from now to the future
Chien-Ching Hung (Taiwan)
Oral Session 6
Moderators: Mario Ramirez (Portugal); Chih-Jung Chen (Taiwan)

OS 6-1 Phenotypic and genotypic characterisation of ribotype 251 strains of Clostridium difficile causing severe disease in the Australian community
Stacey Hong (Australia)

OS 6-2 Timeliness and completeness of molecular screening among populations with a high risk of multidrug resistant tuberculosis in 2010-2015, Taiwan
Pei-Chun Chan (Taiwan)

OS 6-3 First major trichinellosis outbreak in Japan in 35 years
Katsushige Tada (Japan)

OS 6-4 Importance of vaccine serotypes and emergence of non-vaccine serotypes causing non-invasive pneumococcal pneumonia in adults in Portugal (2012-2015)
Mario Ramirez (Portugal)

OS 6-5 The genotype of Coxiella burnetii in human Q fever cases is closer to goats than cattle in southern Taiwan
Chung-Hsu Lai (Taiwan)

OS 6-6 Impact of the 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia and pneumococcal pneumonia in children in Japan
Naruhiko Ishiwada (Japan)

OS 6-7 Barriers and facilitators to tuberculosis examination among homeless people in Osaka city, Japan
Chiyoung Hwang (Japan)

OS 6-8 Prevalence of mcr-1 in Escherichia coli and Klebsiella pneumoniae isolated from food animals in four provinces of China
Ruobing Wang (China)

Satellite Symposium 6
Leading the fight against MRSA and TB through a cutting edge regimen
Organised by Sanofi Taiwan Co., Ltd.
Moderators: Ian M. Gould (United Kingdom); Min-Chi Lu (Taiwan)

SS 6-1 Update on control of MRSA
Ian M. Gould (United Kingdom)

SS 6-2 Glycopeptide selection to treat MRSA infection
Xiao-Jun Ma (China)

SS 6-3 The 3HP regimen in treating latent TB: Taiwan experience sharing
Hsin-Yun Sun (Taiwan)
### Satellite Symposium 7
Quantitative syphilis diagnostics
Organised by Sekisui Medical Co., Ltd.
Moderators: Kazuhisa Osato (Japan); Jang-Jih Lu (Taiwan)

<table>
<thead>
<tr>
<th>SS 7-1</th>
<th>Mediace RPR/TPLA: Product characteristics and status of use in Japan and Korea</th>
</tr>
</thead>
<tbody>
<tr>
<td>SS 7-2</td>
<td>Current status of sexually transmitted disease - focusing on syphilis and serological testing</td>
</tr>
<tr>
<td>SS 7-3</td>
<td>Current developments in sexually transmitted diseases - Focus on Syphilis and serological testing</td>
</tr>
</tbody>
</table>

*Osamu Hirata (Japan)*

*Kazuhisa Osato (Japan)*

*Young Joo Cha (Korea)*
08:50-09:30  Plenary Hall

**Plenary Lecture 3**
**Moderator:** Yin-Ching Chuang (Taiwan)

*Zika virus: update*
*Didier Musso (France)*

09:30-10:00  Plenary Hall

**Keynote Lecture 9**
**Moderator:** Tzou-Yien Lin (Taiwan)

*Vaccines for HPV: the first 10 years*
*Mario Poljak (Slovenia)*

09:30-10:00  Room 201ABC

**Keynote Lecture 10**
**Moderator:** Hsieh-Shong Leu (Taiwan)

*Infection prevention and quality*
*Moi Lin Ling (Singapore)*

09:30-10:00  Room 201DEF

**Keynote Lecture 11**
**Moderator:** Wen-Chien Ko (Taiwan)

*Clostridium difficile: epidemiology, diversity and evolution in Asia*
*Thomas Riley (Australia)*

09:30-10:00  Room 102

**Keynote Lecture 12**
**Moderator:** Jih-Haw Chou (Taiwan)

*Global patterns of MDR-TB evolution*
*Keira Cohen (United States)*

10:30-12:00  Plenary Hall

**Symposium 9**

*Dengue: old disease in children, new disease in adults*
*Co-organised by the Infectious Disease Association of Thailand (IDAT)*
**Moderators:** Terapong Tantawichien (Thailand); Yhu-Chering Huang (Taiwan)

**SP 9-1**  Dengue overview: disease and prevention
*Usa Thisyakorn (Thailand)*

**SP 9-2**  Dengue in adults and travellers
*Terapong Tantawichien (Thailand)*

**SP 9-3**  Dengue vaccines: current clinical perspective
*Daniel Goh (Singapore)*
### Symposium 10
**HAI prevention and control**  
Co-organised by the Asia Pacific Society of Infection Control (APSIC)  
Moderator: Moi Lin Ling (Singapore); Muh-Yong Yen (Taiwan)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>SP 10-1</td>
<td>Control of VAP and CAUTI in Taiwan</td>
<td>Chun-Ming Lee (Taiwan)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 10-2</td>
<td>Evidence and pre-requisite for successful prevention of CLABSI</td>
<td>Anucha Apisarnthanarak (Thailand)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 10-3</td>
<td>How to prevent HAIs when designing a new hospital</td>
<td>Glenys Harrington (Australia)</td>
</tr>
</tbody>
</table>

### Symposium 11
**Combating antimicrobial resistant pathogens**  
Co-organised by the Japanese Society of Chemotherapy (JSC)  
Moderators: Yoshio Takesue (Japan); Doo-Ryeon Chung (Korea)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Country</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>SP 11-1</td>
<td>Japan</td>
<td>Hiroshige Mikamo (Japan)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 11-2</td>
<td>Korea</td>
<td>Doo-Ryeon Chung (Korea)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 11-3</td>
<td>China</td>
<td>Bo Zheng (China)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 11-4</td>
<td></td>
<td>New diagnostics for drug resistant pathogens: present and future</td>
</tr>
</tbody>
</table>

### Symposium 12
**How to get your paper published**  
Co-organised by Elsevier  
Moderators: Fiona Macnab (United Kingdom); Hsin-Chih Lai (Taiwan)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>What do editors look for?</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30</td>
<td>SP 12-1</td>
<td>What do editors look for?</td>
<td>John McConnell (United Kingdom)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 12-2</td>
<td>Frequently asked questions</td>
<td>Fiona Macnab (United Kingdom)</td>
</tr>
<tr>
<td>10:30</td>
<td>SP 12-3</td>
<td>Ask the editors</td>
<td>John McConnell (United Kingdom, LID)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Jean-Marc Rolain (France, IJAA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Stefania Stefani (Italy, JGAR)</td>
</tr>
</tbody>
</table>
Oral Session 7
Moderators: Matthew Dryden (United Kingdom); Ming-Li Liou (Taiwan)

OS 7-1  Pharmacodynamic comparison of antibiotic activity against *Pseudomonas aeruginosa* in models of persistent infection (intracellular infection, biofilm)
         Paul Tulkens (Belgium)

OS 7-2  In vitro activity of cefiderocol against Gram negative clinical isolates collected from Asia and South Pacific in 2014-2016 (SIDERO-CR Study)
         Yoshinori Yamano (Japan)

OS 7-3  In vitro activities of cefiderocol (S-649266), ceftazidime-avibactam, ceftolozane-tazobactam, and other comparative drugs against *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* associated with bloodstream infections
         Shun-Chung Hsueh (Taiwan)

OS 7-4  Antifungal effect of K21 antimicrobial compound against fluconazole-resistant oral *Candida* isolates from HIV+ patients
         Cathy John (South Africa)

OS 7-5  The antimicrobial susceptibility of *Neisseria gonorrhoeae* to faropenem; a arbapenem
         Yoshiki Hiyama (Japan)

OS 7-6  A population-based cohort study on the drug specific effect of statins on sepsis outcome
         Meng-Tse Lee (Taiwan)

OS 7-7  Treatment strategy against MSSA in our hospital
         Akihisa Nakamura (Japan)

OS 7-8  *In vitro* synergistic activities of rifabutin with clarithromycin, imipenem-cilastin and tigecycline against the *Mycobacterium abscessus* complex
         Aristine Cheng (Taiwan)

12:15-13:45  Room 201ABC

Satellite Symposium 8
From empiric therapy to defined treatment
Organised by TTY Biopharm Company Ltd.
Moderators: Ming-Guei Wang (China); Cheng-I Liu (Taiwan)

SS 8-1  Empirical treatment for nosocomial pneumonia and intra-abdominal infections
         Ming-Guei Wang (China)

SS 8-2  Defined treatment for MRSA and VRE bloodstream infections
         David M. Livermore (United Kingdom)

SS 8-3  Defined treatment for MDR-GNB pneumonia and bacteraemia
         Yi-Tsung Lin (Taiwan)
### Satellite Symposium 9

**New insights into empiric antibiotic therapy in respiratory tract infection**
Organised by Daiichi Sankyo Co., Ltd.

**Moderators:** Lionel Ari Mandell (Canada); Yung-Ching Liu (Taiwan)

**Epidemiology of hospital-acquired pneumonia: up-to-date data from China**  
*Hui Wang (China)*

**Recent treatment trend of empiric therapy for severe pneumonia: a perspective from Taiwan**  
*Shih-Chi Ku (Taiwan)*

**Hospital-acquired pneumonia: what’s new in 2017?**  
*Lionel Ari Mandell (Canada)*

---

### Satellite Symposium 10

**Continual immunisation throughout life: from children, adolescents to adults**
Organised by Sanofi Taiwan Co., Ltd.

**Moderators:** Daniel Goh Yam Thiam (Singapore); Tzou-Yien Lin (Taiwan)

**SS 10-1**  
Pertussis among adolescents and adults  
*Cheng-Hsun Chiu (Taiwan)*

**SS 10-2**  
Shifting epidemiology of Japanese encephalitis: the importance of adult boosters  
*Hee Soo Kim (South Korea)*

**SS 10-3**  
Extra protection against influenza: quadrivalent influenza vaccines  
*Daniel Goh Yam Thiam (Singapore)*

---

### Satellite Symposium 11

**Laboratory diagnostics of sepsis**
Organised by Becton Dickinson Company

**Moderators:** Wing Hong Seto (Hong Kong); Kao-Pin Hwang (Taiwan)

**SS 11-1**  
Using informatics to optimise sepsis diagnosis workflow  
*Yun F (Wayne) Wang (USA)*

**SS 11-2**  
Blood volume and blood culture positive rates  
*Raymond Leung (Hong Kong)*

**SS 11-3**  
A new era for infection control: molecular diagnosis  
*Yu-Jiun Chan (Taiwan)*
14:00-14:30
Keynote Lecture 13
Moderator: Serhat Unal (Turkey)
Antimicrobial stewardship practice in Taiwan
Yin-Ching Chuang (Taiwan)

14:00-14:30
Keynote Lecture 14
Moderator: TBA
TBA

14:00-14:30
Keynote Lecture 15
Moderator: Jen-Jyh Lee (Taiwan)
MDR/XDR TB treatment update
Chen-Yuan Chiang (IUAT)

14:00-14:30
Keynote Lecture 16
Moderator: Chun-Ming Lee (Taiwan)
Reactive oxygen therapy, a serious antibiotic alternative?
Matthew Dryden (United Kingdom)

14:30-16:00
Symposium 13
Drug resistance in the microbial world
Co-organised by the European Society of Clinical Microbiology and Infectious Disease (ESCMID)
Moderators: Mario Poljak (Slovenia); Jen-Ren Wang (Taiwan)

SP 13-1
Antibacterial resistance: current status and future perspectives
Giuseppe Cornaglia (Italy)

SP 13-2
Antiviral resistance: new drugs, new problems?
Mario Poljak (Slovenia)

SP 13-3
Beyond antibiotics: new therapeutic approaches for bacterial infections
Alan Hauser (United States)

14:30-16:00
Symposium 14
The expanding global problem of antifungal resistance
Co-organised by the ISC Infection Prevention and Control Working Group
Moderators: TBA; Jien-Wei Liu (Taiwan)

SP 14-1
Azole resistance in Aspergillus fumigatus
Jacques F. Meis (Netherlands)

SP 14-2
Emerging resistance in Candida
Yee-Chun Chen (Taiwan)

SP 14-3
Rare fungal pathogens beyond Aspergillus and Candida
Anuradha Chowdhary (India)
Symposium 15
Antimicrobial stewardship in Asia
Co-organised by the Japanese Society of Chemotherapy (JSC)
Moderators: Hiroshi Kiyota (Japan); Vincent Cheng (Hong Kong)

SP 15-1 Japan
Satoshi Takahashi (Japan)

SP 15-2 Korea
Hyungmin Lee (Korea)

SP 15-3 Singapore
David Chien Boon Lye (Singapore)

SP 15-4 Development of new antibiotics
Kazuhiro Tateda (Japan)

Symposium 16
Infections/outbreaks and the world refugee crisis
Co-organised by the ISC Working Group on Infections in Catastrophic Areas
Moderators: Didier Musso (France); Wing-Wai Wong (Taiwan)

SP 16-1 Lessons from South Sudan: tribal conflicts and outbreaks of infectious diseases internally displace populations
Andrea Shahum (Cambodia)

SP 16-2 Screening of HIV, TB, HBV among migrants on the Balkan route
Vladimir Krcmery (Slovakia)

SP 16-3 Vaccination and war conflicts in Lebanon, Syria and Iraq
Jozef Suvada (Lebanon)

Oral Session 8
Moderators: Subramanian Swaminathan (India); Chi-Shih Chu (Taiwan)

OS 8-1 Capsular serotype and polysaccharide production in hyper-virulent K. pneumoniae strains from bacteraemias in Japan
Atsushi Togawa (Japan)

OS 8-2 Placental macrophages in HIV-1-infected women receiving highly active anti-retroviral therapy (HAART): immunohistochemical evidence of protective role in materno-foetal HIV transmission
Moses Kapembwa (United Kingdom)

OS 8-3 Sensitivity of MRSA isolates for ultra-diluted homeopathic medicines in in-vitro conditions
Ganesh Lakshmanan (India)

OS 8-4 Comparative analysis of large clostridial toxin negative, CDT producing C. difficile strains
Grace O Androga (Australia)

OS 8-5 Pathogenic role of stringent response in oxidative stress response and biofilm formation of Helicobacter pylori
Shigeru Kamiya (Japan)
OS 8-6  Chimeric virulence and antimicrobial-resistant plasmid pOU7519 in *Salmonella enteritica* serovar Choleraesuis  
Chyi-Liang Chen (Taiwan)

OS 8-7  Solithromycin inhibits MUC5AC production induced by *Streptococcus pneumoniae* and *Haemophilus influenzae* in human airway epithelial cells  
Kenji Ota (Japan)

14:30-16:00  South Lounge
Oral Session 9  
Moderators: Susan S Huang (United States); Yuarn-Jang Lee (Taiwan)

OS 9-1  Long term effects of oral antibiotic prophylaxis for colorectal surgery on the frequencies and trends of bacteria isolated from patients in a surgical ward  
Hiroaki Hata (Japan)

OS 9-2  Association between positive culture results during admission and one-year mortality in critically ill cancer patients  
Hsiu-Yin Chiang (Taiwan)

OS 9-3  Strict glycaemic control to prevent surgical site infections in gastroenterology surgery in patients with and without diabetes mellitus  
Toshie Tsuchiida (Japan)

OS 9-4  Effectiveness of antibacterial linen in prevention of hospital acquired infections  
Trang Dang Thi Van (Vietnam)

OS 9-5  Administration of antimicrobials affects the nasal bacterial flora in ICU patients  
Shuichi Abe (Japan)

OS 9-6  Retrospective analysis of antibacterial treatment for infectious disease of elderly and very elderly patients  
Kazuki Taoka (Japan)

OS 9-7  Tracking a nosocomial Carbapenem-Resistant Klebsiella Pneumoniae outbreak by whole-genome sequencing  
Qi Wang (China)

16:30-18:00  Plenary Hall
Oral Session 10  
Moderators: Paul Tulkens (Belgium); Susan Shin-Jung Lee (Taiwan)

OS 10-1  *Campylobacter fetus*-infected aneurysm: case report and literature review 1971–2016  
Kiyozumi Suzuki (Japan)

OS 10-2  *Staphylococcus argenteus*, an emerging pathogen of community-onset bacteraemia associated with high mortality  
Chien-Yu Chi (Taiwan)

OS 10-3  Bacteraemia in patients over 90 years of age  
Yuji Hirai (Japan)

OS 10-4  β-lactams versus glycopeptides for the treatment of *Enterococcus faecalis* bacteraemia  
Yu-Ping Wang (Taiwan)

OS 10-5  Cerebral syphilitic gumma can arise within months of re-infection: a case of histologically proved Treponema pallidum strain type 14b/f infection with HIV positivity  
Yusuke Koizumi (Japan)
Clinical characteristics, microbiology and outcomes of patients with severe influenza during the 2016 flu endemic in Taiwan
Ching-Yuan Yeh (Taiwan)

Corynebacterium blood stream infection among haematological malignancy patients with neutropenia: a case series analysis
Hiroyuki Takahashi (Japan)

Role of environmental surveillance in communal areas after a hospital outbreak of multidrug-resistant Acinetobacter baumannii in Hong Kong
Shuk Ching Wong (Hong Kong)

Antibiotic-Resistant Gram Negative Bacteria in Asia: Catch me if you can
Visanu Thamlikitkul (Thailand)

Beta lactam - beta lactamase inhibitors (BL-BLIs) – what is their role in antimicrobial stewardship?
Tony Korman (Australia)

Empiric therapy in cIAI-cUTI: what is needed to get it right?
Rontgene M. Solante (Philippines)

Contribution of horizontal gene transfer to the spread of VIM-4 carbapenemase producer Enterobacteriaceae in Kuwait
Agnes Sonnevend (United Arab Emirates)

Ampicillin plus ceftriaxone could safely treat infective endocarditis caused by Enterococcus faecalis
Hanako Yoshihara (Japan)

The emergence of Klebsiella pneumoniae ST14, ST147 and ST231 clones among carbapenem-resistant Enterobacteriaceae isolated between 2009 and 2015 in Abu Dhabi, UAE
Tibor Pal (United Arab Emirates)

Genome wide dissection of S. pneumoniae non-susceptible to a wide range of β-lactam antibiotics, circulating among preschool children in central Vietnam
Hiroshi Fujii (Japan)

The emergence of hyper virulent and antimicrobial-resistant capsular type K1 Klebsiella pneumoniae strains in Taiwan
Yi-Tsung Lin (Taiwan)

Is there a global increase in resistance to antibiotics? A snapshot of resistance from 2014 to 2016 in Marseille, France
Stephanie Le Page (France)
16:30-18:00 Room 102
Satellite Symposium 13
Microbiota and probiotics
Organised by Maywufa
Moderators: Kazuhiro Tateda (Japan); Yen-Hsu Chen (Taiwan)

Probiotics in Taiwan from bench to clinical
Chun-Yan Yeung (Taiwan)

The role of probiotics in the control and prevention of MDROs
Shey-Ying Chen (Taiwan)

C. difficile infection
Kazuhiro Tateda (Japan)

16:30-18:00 Room 103
Satellite Symposium 14
Latest improvement of automated environmental control in approaching zero tolerance of healthcare-associated infection
Organised by Chriskey Biomedical Technology Corporation
Moderators: Victor Lim (Malaysia); Wen-Sen Lee (Taiwan)

SS 14-1 Environmental associated MDRO nosocomial infections
Victor Lim (Malaysia)

SS 14-2 Significance of environmental decontamination
Ping-Ing Lee (Taiwan)

SS 14-3 Nanotechnology in environmental disinfection
Muh-Yong Yen (Taiwan)
Monday, 27 November

08:50-09:30
Plenary Lecture 4
Moderator: Lee-Jene Teng (Taiwan)
Novel technologies and diagnostic methods in AMR era
Kazuhiro Tateda (Japan)

09:30-10:00
Keynote Lecture 17
Moderator: Raphael Saginur (Canada)
Antibiotic resistance has a language problem
Marc Mendelson (South Africa)

09:30-10:00
Keynote Lecture 18
Moderator: Cheng-Hsun Chiu (Taiwan)
Vaccines for travel, vaccines for adults: moving targets!
David McIntosh (United Kingdom)

09:30-10:00
Keynote Lecture 19
Moderator: Yen-Hsu Chen (Taiwan)
Reducing device associated infections – the case of catheter associated urinary tract infections
Paul Tambyah (Singapore)

09:30-10:00
Keynote Lecture 20
Moderator: Ching-Chuan Liu (Taiwan)
Viral and host factors involved in enterovirus 71 infection – potential applications in therapy and prophylaxis
Shin-Ru Shih (Taiwan)

10:30-12:00
Symposium 17
Emerging zoonotic viral infections: MERS, swine, equine, and canine influenza and Zika
Co-organised by the ISC Zoonoses Working Group
Moderators: Alfonso J. Rodriguez-Morales (Colombia); Po-Yen Chen (Taiwan)

SP 17-1 MERS-CoV and mass gathering events
Ziad A. Memish (Kingdom of Saudi Arabia)

SP 17-2 Swine, equine, and canine influenza: should we consider changes in these virus as public health threats?
Yi-Chun Lo (Taiwan)

SP 17-3 Zika: epidemiology, complications and the experience in Latin America
Alfonso J. Rodriguez-Morales (Colombia)
### Symposium 18
State-of-the art: *Pneumococcal* diseases and vaccination
Co-organised by the ISC Vaccines Working Group
Moderators: David McIntosh (United Kingdom); Li-Min Huang (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 18-1</td>
<td>Global burden of <em>Pneumococcal</em> diseases</td>
<td>Mario Ramirez (Portugal)</td>
</tr>
<tr>
<td>SP 18-2</td>
<td><em>Pneumococcal</em> vaccination in Asia: current status</td>
<td>Ping-Ing Lee (Taiwan)</td>
</tr>
<tr>
<td>SP 18-3</td>
<td><em>Pneumococcal</em> vaccines for adults</td>
<td>Atef M. Shibi (Saudi Arabia)</td>
</tr>
</tbody>
</table>

### Symposium 19
Using PK/PD to optimise therapy
Co-organised by the ISC Infections in the ICU and Sepsis Working Group
Moderators: Pierre Tattevin (France); Chang-Pan Liu (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 19-1</td>
<td>Antibiotic dosing in patients receiving RRT and ECMO</td>
<td>Francesco Scaglione (Italy)</td>
</tr>
<tr>
<td>SP 19-2</td>
<td>TDM and pharmacokinetics of triazoles</td>
<td>Shu-Wen Lin (Taiwan)</td>
</tr>
<tr>
<td>SP 19-3</td>
<td>Population pharmacokinetic and pharmacodynamics analyses of glycopeptides</td>
<td>TBA</td>
</tr>
</tbody>
</table>

### Symposium 20
Hot topics in urogenital tract infections
Co-organised by the ISC UTI Working Group
Moderators: Florian Wagenlehner (Germany); Stephen Yang (Taiwan)

<table>
<thead>
<tr>
<th>Session</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP 20-1</td>
<td>Antibiotic resistance is a major problem in the management of urogenital infections</td>
<td>Shingo Yamamoto (Japan)</td>
</tr>
<tr>
<td>SP 20-2</td>
<td>Novel antibiotics in the treatment of urinary tract infections</td>
<td>Florian Wagenlehner (Germany)</td>
</tr>
<tr>
<td>SP 20-3</td>
<td>Are UTI managed differently in Asia, Europe and America?</td>
<td>Seung-Ju Lee (South Korea)</td>
</tr>
<tr>
<td>SP 20-4</td>
<td>Ibuprofen versus fosfomycin for uncomplicated urinary tract infection in women: randomised controlled trial</td>
<td>Ildikó Gágyor (Germany)</td>
</tr>
<tr>
<td>Oral Session 12</td>
<td>Moderators: Glenys Harrington (Australia); Zhi-Yuan Shi (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| **OS 12-1**     | STEREX® S: A novel efficient disinfectant formulation against antibiotic-resistant microbial pathogens  
| **Moderator**   | Chalermpong Saenjum (Thailand)                                |
| **OS 12-2**     | Challenges and successes: TB infection control programme implementation at an academic medical centre in Saudi Arabia: a multidisciplinary process improvement project  
| **Moderator**   | Ashraf Khan (Saudi Arabia)                                    |
| **OS 12-3**     | Risk factors and molecular epidemiology of *Acinetobacter baumannii* bacteraemia in neonates  
| **Moderator**   | Hao-Yuan Lee (Taiwan)                                         |
| **OS 12-4**     | Central nervous system complications in infective endocarditis; serum ferritin levels can be a simple predictor?  
| **Moderator**   | Yuji Hirai (Japan)                                            |
| **OS 12-5**     | Characterization of rifampin-resistant *Staphylococcus aureus* nasal carriage in patients receiving rifampin-containing regimens for tuberculosis  
| **Moderator**   | Yu-Tsung Huang (Taiwan)                                       |
| **OS 12-6**     | Aetiology of CNS infections in Nepal using the FilmArray meningitis/encephalitis panel  
| **Moderator**   | Olof Sall (Sweden)                                            |

<table>
<thead>
<tr>
<th>Oral Session 13</th>
<th>Moderators: Raphael Saginur (Canada); Luan-Yin Chang (Taiwan)</th>
</tr>
</thead>
</table>
| **OS 13-1**     | Impact of inappropriate empiric antibiotic therapy on the mortality in paediatric patients with bloodstream infections  
| **Moderator**   | Michihito Kyo (Japan)                                         |
| **OS 13-2**     | Acute gastroenteritis in hospitalised children in southern Taiwan: emphasis on *Clostridium difficile* related acute gastroenteritis  
| **Moderator**   | Fu- Chun Kuo (Taiwan)                                         |
| **OS 13-3**     | Impact of infectious diseases consultation within 10 days and outcome of length of inpatient hospital stay among patients with infective endocarditis  
| **Moderator**   | Yuichi Takahashi (Japan)                                      |
| **OS 13-4**     | Adenovirus detection in paediatric community acquired pneumonia in Taiwan during 2010 to 2015  
| **Moderator**   | Ching-Fen Shen (Taiwan)                                       |
| **OS 13-5**     | Changes in quinolone susceptibility of *Streptococcus pneumoniae* isolated from community-acquired pneumococcal pneumonia in children <5 years of age: influence of oral fluoroquinolone granules for children in Japan  
| **Moderator**   | Noriko Takeuchi (Japan)                                       |
| **OS 13-6**     | Extended-spectrum β-lactamase-producing *Escherichia coli* bacteraemia: comparison of paediatric and adult populations  
| **Moderator**   | Ming-Fang Cheng (Taiwan)                                      |